Texas House Bill HB2229

Texas 2011 - 82nd Regular

• Introduced: 3/4/11
• Out of House Committee: 4/11/11
• Voted on by House: 4/27/11
• Refer: 3/10/11
• Out of Senate Committee: 5/11/11
• Report Pass: 4/5/11
• Voted on by Senate: 5/16/11
• Engrossed: 4/27/11
• Governor Action: 6/17/11
• Refer: 4/28/11
• Report Pass: 5/11/11
• Enrolled: 5/18/11
• Passed: 6/17/11

Caption

Relating to the creation of the Texas HIV Medication Advisory Committee.

Impact

The establishment of the Texas HIV Medication Advisory Committee is expected to have significant implications for public health policy in Texas. By formalizing the advisory process related to HIV treatment and medication access, the bill seeks to enhance the state's response to the HIV epidemic. It is anticipated that the committee's recommendations will streamline processes and improve medication availability and support for affected individuals, thereby positively affecting the quality of care received by patients across the state.

Summary

House Bill 2229 aims to create the Texas HIV Medication Advisory Committee, which will function under the Health and Safety Code. This committee will be comprised of 11 members appointed by the executive commissioner of the Health and Human Services Commission, including medical professionals, consumers diagnosed with HIV, and a social worker. The primary role of this committee will be to provide guidance and recommendations on the Texas HIV medication program, with a focus on assessing ongoing efforts and setting future objectives aimed at meeting the medication needs of those affected by HIV.

Contention

Although the bill has garnered support for its potential benefits to public health, there may be concerns regarding the effectiveness of the committee in representing patient voices adequately. The inclusion of consumer representatives is a step towards ensuring that the experiences of those living with HIV are heard; however, critics may argue that the structure requires careful oversight to ensure that it operates transparently and effectively. Additionally, the transition from previous advisory mechanisms may raise questions about continuity in support and resources for those affected by HIV.